Next Article in Journal
Role of CYP2C9, CYP2C19 and EPHX Polymorphism in the Pharmacokinetic of Phenytoin: A Study on Uruguayan Caucasian Subjects
Next Article in Special Issue
Comparison of In Vitro Assays in Selecting Radiotracers for In Vivo P-Glycoprotein PET Imaging
Previous Article in Journal
Glycosaminoglycan Interactions with Chemokines Add Complexity to a Complex System
Previous Article in Special Issue
Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between 99mTc-Bone-Scintigraphy and [68Ga]Ga-PSMA PET/CT
Article Menu
Issue 3 (September) cover image

Export Article

Open AccessArticle
Pharmaceuticals 2017, 10(3), 72; doi:10.3390/ph10030072

Folate Receptor-Positive Gynecological Cancer Cells: In Vitro and In Vivo Characterization

1
Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institut, Villigen-PSI 5232, Switzerland
2
Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich 8093, Switzerland
*
Author to whom correspondence should be addressed.
Received: 6 May 2017 / Revised: 31 July 2017 / Accepted: 9 August 2017 / Published: 15 August 2017
View Full-Text   |   Download PDF [2426 KB, uploaded 17 August 2017]   |  

Abstract

The folate receptor (FR) is expressed in a variety of gynecological cancer types. It has been widely used for tumor targeting with folic acid conjugates of diagnostic and therapeutic probes. The cervical KB tumor cells have evolved as the standard model for preclinical investigations of folate-based (radio) conjugates. In this study, a panel of FR-expressing human cancer cell lines—including cervical (HeLa, KB, KB-V1), ovarian (IGROV-1, SKOV-3, SKOV-3.ip), choriocarcinoma (JAR, BeWo) and endometrial (EFE-184) tumor cells—was investigated in vitro and for their ability to grow as xenografts in mice. FR-expression levels were compared in vitro and in vivo and the cell lines were characterized by determination of the sensitivity towards commonly-used chemotherapeutics and the expression of two additional, relevant tumor markers, HER2 and L1-CAM. It was found that, besides KB cells, its multiresistant KB-V1 subclone as well as the ovarian cancer cell lines, IGROV-1 and SKOV-3.ip, could be used as potentially more relevant preclinical models. They would allow addressing specific questions such as the therapeutic efficacy of FR-targeting agents in tumor (mouse) models of multi-resistance and in mouse models of metastases formation. View Full-Text
Keywords: folate receptor; folic acid; ovarian cancer; cervical cancer; endometrial cancer; choriocarcinoma, KB; KB-V1; IGROV-1; SKOV-3; SKOV-3.ip folate receptor; folic acid; ovarian cancer; cervical cancer; endometrial cancer; choriocarcinoma, KB; KB-V1; IGROV-1; SKOV-3; SKOV-3.ip
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Siwowska, K.; Schmid, R.M.; Cohrs, S.; Schibli, R.; Müller, C. Folate Receptor-Positive Gynecological Cancer Cells: In Vitro and In Vivo Characterization. Pharmaceuticals 2017, 10, 72.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top